Furthermore, histone deacetylase (HDAC) inhibitors have gained attention due to their ability to downregulate the microphthalmia-associated transcription factor (MITF), which plays a crucial role in melanoma progression and therapeutic resistance. This evidence concerns the gene HDAC9 and melanoma.